View article

Multiphase CT or MR imaging is the mainstay in diagnosis, staging, and surveillance of patients with hepatobiliary and pancreatic malignancies.[18F] Fluorodeoxyglucose (FDG) PET/CT offers added value in therapeutic decision-making and in determining prognosis. Several studies have shown that non-FDG tracers such as gallium-68 (68Ga)-labeled fibroblast activation protein (FAP) inhibitor (FAPI) PET/CT have potential in diagnosis, staging, and possibly radioligand therapy of hepatobiliary and pancreatic malignancies.